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The relationship between medicine and the study of life is as old as medicine itself.
Nevertheless, historians have highlighted the great transformation that took place in
the nineteenth century when first physiology and then bacteriology became important
resources for the classification, diagnosis, and treatment of human diseases.
1 In that
period, significant links developed between the sites specializing in biological experi-
mentation (i.e. laboratories) on the one hand, and the places of healing (i.e. hospitals,
dispensaries) and public health offices on the other. Together, they helped to fashion
modern, professional medicine.
2 However, many historical studies have also argued
that this mobilization of biological knowledge exerted a limited impact on medical prac-
tice in general, and clinical practice in particular.
3
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1W F Bynum, Science and the practice of
medicine in the nineteenth century, Cambridge
University Press, 1994; idem, ‘The rise of science in
medicine, 1850–1913’, in W F Bynum, Anne Hardy,
Stephen Jacyna, Christopher Lawrence, and E M
Tansey, The western medical tradition 1800 to
2000, Cambridge University Press, 2006,
pp. 103–230.
2The development of medicine as a modern
profession has been discussed most thoroughly in
relation to the United States and Germany; on the
American example, see John Harley Warner, The
therapeutic perspective: medical knowledge,
practice, and professional identity in America,
1820–1885, Cambridge, MA, Harvard University
Press, 1984; on Germany, see Charles E McClelland,
The German experience of professionalization:
modern learned professions and their organizations
from the early nineteenth century to the Hitler era,
Cambridge University Press, 1991; on France:
Matthew Ramsay, ‘The politics of professional
monopoly in nineteenth-century medicine: the French
model and its rivals’, in Gerald L Geison (ed.),
Professions and the French state, 1700–1900,
Philadelphia, University of Pennsylvania Press, 1984;
on Britain: Ivan Waddington, The medical profession
in the industrial revolution, Dublin, Gill and
Macmillan, 1984.
3For historical overviews of clinical research, see
Christopher C Booth, ‘Clinical research’, in
W F Bynum and Roy Porter (eds), Companion
encyclopedia of the history of medicine, London and
New York, Routledge, 1990, vol. 1, pp. 205–9;
Christiane Sinding, Le clinicien et le chercheur: des
grandes maladies de carence a ` la me´decine
mole´culaire, Paris, PUF, 1991; Christopher
Lawrence, ‘Clinical research’, in John Krige and
Dominique Pestre (eds), Science in the twentieth
century, Amsterdam, Harwood Academic, 1997,
pp. 439–59. See also Christopher Lawrence and
George Weisz (eds), Greater than the parts: holism
in medicine, 1920–1950, Oxford University Press,
1998.
441The well-documented history of bacteriology is emblematic of these conflicting
trends. While one may point out the importance of widely circulated and celebrated
innovations, such as bacteriological cultures and diagnoses, or a few but impressive
therapeutic agents like diphtheria antitoxin, bacteriology itself did not have a radical
impact on early-twentieth-century public health.
4 The history of tuberculosis in industrial
Europe is a powerful—and often mentioned—illustration of this. The bacteriological
trajectory of tuberculosis is not only remembered because of the success of animal mod-
elling, which led to the identification of Koch’s bacillus, or because of the effectiveness
of X-rays, which enabled the early detection of tubercular lesions. It is also marked by
the failure of Koch’s tuberculin as a miracle drug, by the controversies surrounding
the efficacy of BCG vaccination and the Lu ¨beck affair, by the uncertainties about the
combined roles of heredity and infection in the aetiology of the disease, as well as by
the enduring domination of public hygiene and palliative care in sanatoria.
5 It is only
after the beginning of the antibiotic era, in the late 1940s and early 1950s, that decisive
improvements in the control of the white plague could be attributed to the conjunction of
chemical and bacteriological work conducted both in academic and industrial labora-
tories.
6 Generalizing from the example of tuberculosis, one can therefore argue that
biomedicine was only truly “invented” after the Second World War.
The transformation of biology and medicine, and their convergence after 1945, is
far from being uncharted territory for historians.
7 Several studies have revealed a step
change in the scale of investment in research, a new role for the state as scientific
4For an introduction to the debates about the
impact of medical science on public health, see
Thomas McKeown, The role of medicine: dream,
mirage, or nemesis?, London, Nuffield Provincial
Hospitals Trust, 1976; Paul Weindling, ‘From
infectious to chronic diseases: changing patterns of
sickness in the nineteenth and twentieth centuries’, in
Andrew Wear (ed.), Medicine in society; historical
essays, Cambridge University Press, 1992,
pp. 303–16; Anne Hardy, ‘On the cusp: epidemiology
and bacteriology at the Local Government Board,
1890–1905’, Med. Hist., 1998, 42: 328–46.
5Christoph Gradmann, Krankheit im Labor:
Robert Koch und die medizinische Bakteriologie,
Go ¨ttingen, Wallstein, 2005; Christian Bonah, Etienne
Lepicard and Volcker Roelcke, La me´decine
expe´rimentale au tribunal, Paris, Editions des
Archives Contemporaines, 2003; Jean-Paul
Gaudillie `re and Ilana Lo ¨wy (eds), Heredity and
infection: a history of disease transmission, London,
Routledge, 1998; Michael Worboys and Flurin
Condrau (eds), Tuberculosis then and now:
interdisciplinary perspectives on a post-modern
plague, forthcoming.
6In addition to Worboys and Condrau (eds), op.
cit., note 5 above, see John E Lesch, The first miracle
drugs: how the sulfa drugs transformed medicine,
Oxford University Press, 2007; Jean-Paul Gaudillie `re,
‘The invention of screening: Bayer, Rho ˆne-Poulenc
und die Geburt von Tuberkulose Therapie nach dem
zweiten Weltkrieg’, Medizinisches Historisches
Journal, forthcoming.
7On biological and medical research after 1945,
see Jean-Paul Gaudillie `re, Inventer la biome´decine: la
France, l’Ame´rique et la production des savoirs du
vivant (1945–1965), Paris, La De ´couverte, 2002
(English translation forthcoming from Yale
University Press); Peter Keating and Alberto
Cambrosio, Biomedical platforms: realigning the
normal and the pathological in late-twentieth-
century medicine, Cambridge, MA, MIT Press, 2003;
Ilana Lo ¨wy, Between bench and bedside: science,
healing and interleukine-2 in a cancer ward,
Cambridge, MA, Harvard University Press, 1996;
Roger Cooter and John Pickstone (eds), Medicine in
the twentieth century, Amsterdam, Harwood
Academic Publishers, 2000; Paul Starr, The social
transformation of American medicine: the rise of a
sovereign profession and the making of a vast
industry, New York, Basic Books, 1982. See also
Anne Hardy and E M Tansey, ‘Medical enterprise and
global response, 1945–2000’, in Bynum, et al., The
western medical tradition, op. cit., note 1 above,
pp. 405–533.
Viviane Quirke and Jean-Paul Gaudillie `re
442entrepreneur, an increasingly fundamental level of investigation in biology and medicine,
and a closer relationship between the laboratory and the clinic. They have also described
the culture of the therapeutic miracle that has pervaded scientific and medical commu-
nities, and inspired the search for magic bullets against tuberculosis, cancer, and cardio-
vascular diseases.
8 In fact, the links between these changes have been such that the
period 1945–1975 could be described as one of a new system of relations between
science, technology and medicine, or as a new “way of knowing”.
9
That the post-war period saw the growth of biomedical complexes characterized by
the intensification of research in the life sciences, the hunt for novel molecules, and a
new alliance between biologists and the state, should not obscure the fact that it also
saw renewed tensions and local variations, which challenge any description of it as the
culmination of a uniform trend. Firstly, there have been tensions between three different
kinds of medicine: experimental medicine, clinical medicine, and social medicine.
Although biomedicine has, above all, been dominated by experimental medicine, other
sets of practices have persisted alongside those employed by the experimenter, including
molecular modelling and analysis, and biomedical scientists have developed complex
relationships with hospital clinicians and public health officials, which have varied
from arms-length distance, to mutual inter-dependence, and—more rarely—to outright
collaboration.
Then, of course, there have been variations due to different local and national contexts.
Whether these have affected the status of medical goods and services, the relationship
between health professionals and the state, the evolution of scientific disciplines and med-
ical specialties, the hierarchy between them, the regulation of the pharmaceutical industry
and the medical market, or simply what is meant by “social”, these different contexts have
influenced the evolution and nature of biomedical complexes. Even within the relatively
homogeneous scientific landscape of post-war Europe, one might therefore expect
national differences to have played a role that has been all the more important in that,
in the decades after the war, the management of life and health became a matter for the
state, exceeding in scale and scope the demographic concerns of earlier governments.
However, as Anne Hardy and Tilli Tansey have rightly pointed out, “there is no satis-
factory general overview of the history of western medicine after 1945”,
10 particularly
8See, for example, David Cantor, ‘Cortisone and
the politics of drama, 1949–1955’, in John V
Pickstone (ed.), Medical innovations in historical
perspective, Basingstoke, Macmillan, 1992,
pp. 163–84; James Le Fanu, The rise and fall of
modern medicine, London, Abacus, 1999; Toine
Pieters, Interferon: the science and selling of a
miracle drug, Abingdon and New York, Routledge,
2005; Lesch, op. cit., note 6 above; Robert Bud,
Penicillin: triumph and tragedy, Oxford University
Press, 2007; Viviane Quirke, ‘From evidence to
market: Alfred Spinks’s 1953 survey of new fields of
pharmacological research, and the origins of ICI’s
cardiovascular programme’, in Virginia Berridge and
Kelly Loughlin (eds), Medicine, the market and the
mass media: producing health in the twentieth
century, London and New York, Routledge, 2005,
pp. 146–71; Viviane Quirke, ‘Putting theory into
practice: James Black, receptor theory and the
development of the beta-blockers at ICI, 1958–1978’,
Med. Hist., 2006, 50: 69–92.
9John V Pickstone, Ways of knowing: a new
history of science, technology and medicine,
Manchester University Press, 2000.
10Anne Hardy and E M Tansey, ‘Bibliographical
essays’, in Bynum, et al., The western medical
tradition, op. cit., note 2 above, pp. 537–64, on
p. 555.
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443concerning the changing relationship between laboratories, clinical settings, and public
health authorities, and taking into account the different countries that have contributed
to the western medical tradition. The purpose of the following collection is therefore
to examine further this changing relationship, as well as encourage the study of bio-
medicine in different national contexts.
The first choice we made in preparing this issue was to concentrate on post-war
clinical and public health research, in order to examine the forces and influences that
fashioned western medicine in the “era of biomedicine”. Biological research and
laboratory investigations have been the subject of much historical work in science
and medicine after 1945, most notably in relation to the so-called “molecularization”
that led biologists to relocate life and its most basic processes at the level of macro-
molecular structures, more especially DNA and genes. Historians of molecular biology
and its parent disciplines, biochemistry, genetics, and virology, have stressed the criti-
cal role that the development of new tools and instrumental practices—such as the use
of the ultracentrifuge, electron microscope, and electrophoresis—have played in this
transformation.
11 These studies have also shown how the “molecular vision” of life
was linked to the political and cultural aspects of the Cold War, its emphasis on infor-
mation and control, and its permanent state of scientific mobilization in preparation for
war.
12 Hence, between 1945 and 1965, biological experimentation changed radically,
even if important fields like embryology and developmental studies proved much
more difficult to attach to the molecular bandwagon than geneticists and biochemists
had hoped.
These developments in the life sciences were not without their consequences for, and
echoes in, medicine. The most obvious was the incorporation of new entities, ranging
from enzymes to cancer viruses and inbred strains of mice, in the aetiological character-
ization of diseases. Despite such advances, the direct impact of molecular biology on
medical practice remained confined to new explanatory models and diagnostic tools.
The most significant displacements were more indirect, resulting from the complex inter-
action between the molecularization of the life sciences and the molecularization of
medical intervention, i.e. the transformation of therapeutic targets and the generalization
of a chemotherapeutic model of treatment, a situation influenced as well as exemplified
by the post-war history of cancer.
13 This aspect of “biomedicine”, in particular the
11Robert E Kohler, Partners in science:
foundations and natural scientists, 1900–1945,
University of Chicago Press, 1991; Lily E Kay, The
molecular vision of life: Caltech, the Rockefeller
Foundation, and the rise of the new biology, Oxford
and New York, Oxford University Press, 1993;
Nicolas Rasmussen, Picture control: the electron
microscope and the transformation of biology in
America, 1900–1960, Stanford University Press,
1997; Pnina G Abir-Am, ‘The molecular
transformation of twentieth-century biology’, in Krige
and Pestre (eds), op. cit., note 3 above, pp. 495–523;
Angela N H Creager, The life of a virus: tobacco
mosaic virus as an experimental model, 1930–1965,
University of Chicago Press, 2002; Soraya de
Chadarevian, Designs for life: molecular biology
after World War II, Cambridge University Press,
2002; Gaudillie `re, op. cit., note 7 above.
12Lily E Kay, Who wrote the book of life? A
history of the genetic code, Stanford University Press,
2000.
13In addition to above mentioned works, see the
collection of essays gathered by David Cantor in the
special issue of the Bulletin of the History of
Medicine (2007, 81 [1]) on cancer after the Second
World War.
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444relationship between the misnamed “therapeutic revolution”—too readily attributed to
the changing scale, organization, and targets of pharmaceutical research—and clinical
and social medicine, which this issue touches upon, largely remains to be explored.
14
The second principle guiding our selection was the particular interest of comparing
Britain with France, for the history of these two countries’ biomedical complexes has
many similar features, such as the relative underdevelopment of certain fields in the
inter-war years, followed by a process of catching up after the Second World War.
15
Yet the differences between Britain and France, not least their different systems of health
care, might be significant enough to lead to distinct but nevertheless related biomedical
practices, partly because none of the developments described above took place in isola-
tion. However, exchanges were less a matter of direct, bilateral “crossed history”, than of
intricate circulation, with the American biomedical complex as third party, functioning at
once as a model, competitor, and provider of means—cognitive and financial, as well as
instrumental—which reflected the economic, political and scientific hegemony of the
United States.
16
The very word “biomedicine”, its emergence and subsequent uses, is a testimony to
these differences. The prominence acquired by the term between 1945 and 1975 co-
incided with the appearance of a new system of medical innovation in relation to biology
and health policy. However, this system was far from homogeneous, and the meaning of
biomedicine has been deeply influenced by the different scientific and national cultures
that have shaped western medicine since the late nineteenth century. In Britain, the word
biomedicine first appeared in Dorland’s 1923 Medical dictionary, and meant “clinical
medicine based on the principles of physiology and biochemistry”.
17 Although in the
inter-war years the term was used only sporadically, it is significant that its invention
14The relationship between drug companies and
clinicians has begun to receive special attention from
historians. See Nicolas Rasmussen, ‘The drug
industry and clinical research in interwar America:
three types of physician collaborator’, Bull. Hist.
Med., 2005, 79: 50–80; Jeremy A Greene,
Prescribing by numbers: drugs and the definition of
disease, Baltimore, Johns Hopkins University Press,
2007; Viviane Quirke, Collaboration in the
pharmaceutical industry: changing relationships in
Britain and France, 1935–1965, Abingdon and New
York, Routledge, 2008, pp. 241–2.
15For a comparative study of the development of
biochemistry, see Robert E Kohler, From medical
chemistry to biochemistry: the making of a
biomedical discipline, Cambridge University Press,
1982. Regarding French and British medical sciences
and the pharmaceutical industry, see Quirke, op. cit.,
note 14 above. Concerning medicine and the life
sciences in France, in addition to already mentioned
works, see Claude Debru, Jean Gayon, and Jean-
Fran¸ cois Picard (eds), Les sciences biologiques et
me´dicales en France, 1920–1950, Paris, CNRS
Editions, 1994; in Britain: Steve Sturdy, ‘Medical
chemistry and clinical medicine: academics and the
scientisation of medical practice in Britain,
1900–1925’, in Ilana Lo ¨wy, Olga Amsterdamska,
John Pickstone and Patrice Pinell (eds), Medicine and
change: historical and sociological studies of medical
innovation, Montrouge, John Libbey Eurotext, and
Paris, INSERM, 1993, pp. 371–93; Soraya de
Chadarevian and Harmke Kaminga (eds),
Molecularizing biology and medicine: new practices
and alliances, 1910s–1970s, Amsterdam, Harwood
Academic Publishers, 1997.
16John Krige, American hegemony and the
postwar reconstruction of science in Europe,
Cambridge, MA, MIT Press, 2006; in relation to
the pharmaceutical industry, see Viviane Quirke,
‘Anglo-American relations and the co-production
of American hegemony in pharmaceuticals’, in
Hubert Bonin and Ferry de Goey (eds), American
firms in Europe, Geneva, Droz, forthcoming,
pp. 306–26.
17Keating and Cambrosio, op. cit., note 7 above,
p. 52.
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445coincided with the Medical Research Council’s move away from public health concerns,
towards biological research.
18 In this period, the “biomedical” work of the Council
consisted in establishing a number of research units, mostly within the London teaching
hospitals, where it promoted a distinct research style inspired by the Cambridge School
of Physiology with the aim of making British clinical medicine more scientific.
19
By contrast, in the French context, the word biomedicine appeared only in the 1960s,
when it was used mainly by science policy makers and state administrators. Paradoxi-
cally, the term was not employed by the biologists involved in the post-war development
of state-funded research agencies (the Centre National de la Recherche Scientifique
(CNRS), or the Institut National d’Hygiene (INH), later Institut National de Sante ´ et
de la Recherche Me ´dicale (INSERM), the French equivalent of the Medical Research
Council [MRC]). On the contrary, they pleaded for a “de-medicalization” of disciplines
such as bacteriology, immunology and virology, whose expansion had, according to
them, been hampered by the influence of “medical mandarins”, and their disciplinary
agenda led them to reject the very idea of “biomedicine”.
20 As for clinicians, they pre-
ferred the term “medical research” (“recherche me´dicale”) to describe what they saw
as a domain based first and foremost on clinical expertise, even if it was influenced by
advances made in the life sciences.
21
The fate of “biomedicine” as a word is a marker of the specific, and yet parallel,
changes that affected the relationship between science, medicine and public health in
Britain and France. Although direct comparisons between the two countries are relatively
rare,
22 the historiography has tended to reinforce the idea of their distinct patterns of evo-
lution. Thus, it has become commonplace to oppose the “nationalization” of the medical
profession and the central planning of health services under the National Health Service
(NHS) to the policy of laissez-faire and professional governance that prevailed with the
Se ´curite ´ Sociale, even if in both cases the creation of a national health system allowed
access to care to the vast majority of the population, and provided the basis upon which
hospitals became the main site for—often high-tech—medical intervention.
23 Similarly,
18Joan Austoker, ‘Walter Morley Fletcher and the
origins of a basic biomedical research policy’, in Joan
Austoker and Linda Bryder (eds), Historical
perspectives on the role of the MRC: essays in the
history of the Medical Research Council of the
United Kingdom and its predecessor, the Medical
Research Committee, 1913–53, Oxford University
Press, 1989, pp. 23–33, and other contributions in this
volume.
19On the MRC’s contribution to British clinical
research, see especially Booth, op. cit., note 3 above,
pp. 205–9.
20Gaudillie `re, op. cit., note 7 above, ch. 8,
pp. 292–317.
21Jean-Fran¸ cois Picard, ‘Pousse ´e scientifique ou
demande de me ´decins? La recherche me ´dicale en
France de l’Institut National d’Hygie `ne a ` l’INSERM:
contributions a ` l’histoire de la recherche me ´dicale en
France au XXe `me sie `cle’, Sciences Sociales et Sante´,
1992, 10: 47–106; idem, ‘De la me ´decine
expe ´rimentale (1865) a ` l’INSERM (1964)’, in Debru,
et al. (eds), op. cit., note 15 above, pp. 329–43, on
p. 342.
22These have mainly dealt with the
pharmaceutical industry, for example, Leigh M
Hancher, Regulating for competition: government,
law and the pharmaceutical industry in the United
Kingdom and France, Oxford, Clarendon, 1990;
Lacy G Thomas, ‘Implicit industrial policy: the
triumph of Britain and the failure of France in
global pharmaceuticals’, Industrial and Corporate
Change, 1994, 3: 451–89; Quirke, op. cit., note 14
above.
23Cooter and Pickstone (eds), op. cit., note 7
above.
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446the expansion of biological and medical research followed different paths in the two
countries: while the French favoured a model of full-time research under the umbrella
of government agencies (the CNRS, INH and later INSERM), the British built on an
older and stronger tradition of university-based research.
24 Furthermore, increasing
post-war investments in experimental medicine had the effect of perpetuating long-
established disciplinary hierarchies, in Britain with the growth of genetics and
biochemistry, and in France with the expansion of the “pasteurian” sciences, namely bac-
teriology, virology and immunology, which after the Second World War came under the
influence of fundamental molecular biology.
25 Last but not least, the extensive use of
medical statistics in Britain, where it was nurtured by a strong public health administra-
tion, contributed to clinical investigations of therapeutic efficacy and regulation of
research practices, which came together in the controlled drug trial, an example rarely
imitated before the late 1970s by the case-loving French clinicians. These observations
drawn from the historiography help to highlight the legitimacy and significance of a com-
parison between Britain and France, particularly in view of the need to examine further
the link between science, medicine and public health in the era of biomedicine.
However, a major paradox resulting from our comparison is that, despite these differ-
ences, French and British biologists and clinicians considered American biomedicine in
much the same way, i.e. as a reference point, a resource, and a challenge. The American
biomedical model is a “ghost” haunting European biomedical research.
26 Its pervading
influence is evident in the reorientation of the circulation of people, tools and results
from a trans-European to a trans-Atlantic direction, and by the realignment of research
practices in western medicine in the years following the war.
27 It is therefore not a com-
plete surprise if the most significant conclusions to emerge from our comparative exer-
cise stress the similarities between Britain and France, for the rise of biomedicine led
to profound changes, which blur the contrasts that have usually been drawn when think-
ing about the two sides of the “medical Channel”.
24Jean-Fran¸ cois Picard, La re´publique des
savants: la recherche fran¸ caise et le CNRS, Paris,
Flammarion, 1990; Picard, ‘Pousse ´e scientifique’, op.
cit., note 21 above; Michael Sanderson, The
universities and British industry, 1850–1970,
London, Routledge and Kegan Paul, 1972; Quirke,
op. cit., note 14 above, Part III; Clive Field and John
Pickstone, A centre of intelligence: the development
of science, technology and medicine in Manchester
and its university, Manchester, John Rylands
University Library of Manchester, 1992; Arthur W
Chapman, The story of a modern university: a
history of the University of Sheffield, London,
Oxford University Press, 1995; Jack Morrell, Science
at Oxford, 1914–1939: transforming an arts
university, Oxford, Clarendon Press, 1997; Mark
Weatherall, Gentlemen, scientists and doctors:
medicine at Cambridge, 1800–1940, Woodbridge,
Boydell Press, 2000.
25See, for example, Michel Morange, Histoire de
la biologie mole´culaire, Paris, La De ´couverte, 1994,
especially ch. 14 on the French school of molecular
biology, and Gaudillie `re, op. cit., note 7 above, chs 7
and 8.
26For a general description of the transformation
of US medicine after 1945, see Starr, op. cit., note 7
above.
27For an example, see Jean-Paul Gaudillie `re,
‘Paris–New York roundtrip: transatlantic crossings
and the reconstruction of the biological sciences in
post-war France’, Stud. Hist. Philos. Biolog.
Biomed. Sci., 2002, 33: 389–417. For a tri-partite
comparison in relation to molecular biology, see
Pnina G Abir-Am, ‘Molecular biology in the context
of British, French, and American cultures’, Inter.
Soc. Sci. J., 2001, 168: 187–99.
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447The most striking similarity, considering the strength of the British tradition in social
medicine, was the re-definition of “public health” as essentially hospital- and drug-based,
or in other words as curative rather than preventive medicine. The papers by John
Stewart and Luc Berlivet show how this convergence emerged out of two different pub-
lic health systems, the first in Britain, the second in France. The creation of the British
NHS in the period of the “classic” welfare state—that is, from the end of the Second
World War to the economic crises of the mid-1970s—produced many new research
opportunities.
28 Stewart’s paper goes on to argue that, important as these opportunities
and the resulting achievements were, there were also considerable constraints, which
affected not only the NHS, but also the MRC operating within it. The opportunities
were in many respects obvious enough—universal health care for British citizens, which
was comprehensive, free at the point of delivery, and accompanied by steadily rising
expenditures. However, the creation of the NHS has been problematic for those with
aspirations to a form of medicine that takes into account the socio-economic environ-
ment, emphasizing prevention rather than cure, and thus overall seeks to deal with health
in an integrated rather than molecular manner. The reasons for this were firstly, financial,
since Britain’s commitment to social medicine was limited even by European standards;
secondly, structural, since in the process of policy formation key influence was handed
over to the medical profession, thus empowering actors who were largely wedded to
the biomedical model, and paid relatively little attention to environmental factors; and
thirdly, political, since although all the major parties were in favour of the NHS in
some form or another, in matters of health policy strategy politicians were not only pre-
pared to cede power to the medical profession, they also conferred a relatively low status
upon the Ministry of Health. All this resulted in a system in which the emphasis was on
curative medicine/biomedicine (particularly in a hospital environment) at the expense of
the interrelated and overlapping fields of preventive medicine/social medicine/public
health/integrated and proactive primary care. Thus, the public health sector and the local
authorities experienced a significant loss of power. Social medicine in particular was dis-
couraged as a discipline, and eventually declined into a version of medical statistics.
29
On this point, Berlivet’s paper converges and intersects with Stewart’s. Berlivet ana-
lyses how the rise of biomedicine impacted on French public health research after the
Second World War. In France, the rise of biomedicine did not depend upon, or lead
to, displacements of concepts, instruments or people; on the contrary. As in the case of
Britain, it was a matter of intellectual and institutional competition between various
forms of health-related enquiries. The INH, established by the Vichy regime but later
maintained and expanded by the political and scientific elites of the Fourth and Fifth
28For an overview of the origins and development
of the NHS, see Charles Webster, The National
Health Service: a political history, Oxford University
Press, 1998. See also Rudolf Klein, The new politics
of the NHS, 3rd ed., London, Longman, 1995;
Geoffrey Rivett, From cradle to grave: fifty years of
the NHS, London, King’s Fund, 1998.
29Dorothy Porter (ed.), Health, civilization and
the state: a history of public health from ancient to
modern times, London, Routledge, 1999. See also
Virginia Berridge, Health and society in Britain
since 1939, Cambridge University Press, 1999; Anne
Hardy, Health and medicine in Britain since 1860,
Basingstoke, Macmillan, 2000.
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448Republics, was initially set up to monitor the health of the French population.
30
This institutional configuration allowed for the development of a wide range of investi-
gations, characterized by an emphasis on the social dimension of disease. However, in
the 1950s and 1960s, changes in the approach to medical research prompted a transfor-
mation of the INH into an institute of biomedicine, a trend that accelerated after it was
renamed the Institut National de Sante ´ et de la Recherche Me ´dicale (INSERM) in
1964. The social and population approach to public health previously adopted by the
INH, and reflected in its large surveys of infectious diseases and later chronic illnesses—
cancer and respiratory disorders among them—was gradually marginalized. At the same
time, the rise of biomedicine encouraged a different kind of population-based research. A
group of medical statisticians built on their links with some influential clinicians and
experimenters to promote a version of epidemiology that concentrated mainly on clinical
trial methodology and on the inferential analysis of complex aetiologies like cancer and
cardiovascular diseases, thus advancing a form of “experimental” medicine typical of the
era of biomedicine, but not biological in essence.
The last two papers deal with yet another similarity that emerges from this compari-
son, namely the common rise of the clinical trial as a privileged form of, and site for,
therapeutic evaluation. The history of clinical trials has begun to move away from the
once overarching concern with methodological innovation and the problematic emer-
gence of statistics as a legitimate form of evidence in medicine. Recent work on the
British aspect of the story has focused on the peculiar history of statistical studies and
clinical research conducted under the aegis of the MRC.
31 The Second World War and
post-war reconstruction, not least with the launch of the NHS in 1948, provided the
MRC with scope and opportunity to expand its activities significantly and venture into
new areas such as cancer, which had previously been dominated by other bodies,
32 as
well as consolidate its role in more traditional fields of study, such as tuberculosis. In
this connection, the MRC trials of streptomycin for the treatment of tuberculosis are
usually seen as a highpoint in the history of modern biomedicine. These trials helped
to establish the Randomized Controlled Trial (RCT) as a gold standard in clinical
research.
33 By contrast, the historiography on the American route to controlled trials
30Jean-Fran¸ cois Picard, ‘Aux origins de
l’INSERM: Andre ´ Chevallier et l’Institut National
d’Hygie `ne et l’INSERM’, Sciences Sociales et Sante´,
2003, 21: 5–26.
31For a British history of clinical trials, see J
Rosser Matthews, ‘Major Greenwood versus Almroth
Wright: contrasting visions of “scientific” medicine in
Edwardian Britain’, Bull. Hist. Med., 1995, 69:
pp. 30–43; idem, Quantification and the quest for
medical certainty, Princeton University Press, 1995;
A Yoshioka, ‘Use of randomisation in the Medical
Research Council’s clinical trial of streptomycin in
pulmonary tuberculosis in the 1940s’, Br. med. J.,
1998, 317: 1220–3; Eileen Magnello and Anne Hardy
(eds), The road to medical statistics, Amsterdam and
New York, Rodopi, 2002; Iain Chalmers and Mike
Clarke, ‘The 1944 patulin trial: the first properly
conducted multicentre trial conducted under the aegis
of the British Medical Research Council’, Inter. J.
Epidemiol., 2004, 33: 253–60.
32On cancer research, see, for example, Joan
Austoker, A history of the Imperial Cancer Research
Fund, 1902–1986, Oxford University Press, 1988.
33Harry M Marks, The progress of experiment:
science and therapeutic reform in the United States,
1900–1990, Cambridge University Press, 1997;
Stefan Timmermans and Marc Berg, The gold
standard: the challenge of evidence-based medicine
and standardization in health care, Philadelphia, PA,
Temple University Press, 2003.
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449has been less interested in randomization and trial design than in clinical work, organiza-
tional change, and drug regulation.
34 The 1962 Kefauver–Harris amendments to the Food
and Drug Act, which provided the Food and Drug Agency (FDA) with a mandate to
enforce investigations of both toxicity and efficacy when examining drug marketing
applications, deeply altered clinical and pharmaceutical research, since “controlled
trials” were made a legal requirement. These amendments were supported by an alliance
of American public health administrators and clinical reformers working in prominent
teaching hospitals, such as those at Harvard and Johns Hopkins, who had long been
searching for instruments of medical evaluation that would at once make clinical practice
more “rational”, and the average practitioner less dependent on the claims of the pharma-
ceutical industry.
35
Parallel studies of the “trial culture” in post-war medicine have concentrated on the
generalization of the RCT in cancer chemotherapy.
36 Although the roots of this evolution
remain equivocal, the industrial origins of cancer chemotherapy as well as the political
context of the American war on cancer have played a crucial role in the success of the
RCT. Clinical investigations of chemotherapeutic treatments were developed by the
National Cancer Institute in association with a mass-screening enterprise, which adopted
a high-throughput approach, and the use of standard molecules, animal models, and
therapeutic protocols.
37 In this context, clinical trials were a means of alignment and
control over heterogeneous local practices. They played an important part in scaling-
up activities and achieving statistical significance, but unexpectedly resulted in a blurring
of the boundaries between the biological modelling of cancer causation and the therapeu-
tic combination of surgery, radiotherapy, and drugs. In addition, clinical trials seemed
particularly well suited to the production of evidence in cases where efficacy was not
a matter of cure but rather a question of survival time, and to the evaluation of palliative
forms of medical intervention, as in the case of cancer.
If the 1947 streptomycin trials are well remembered, it is less well known that the
MRC Tuberculosis Research Unit that oversaw these trials also organized clinical trials
on the treatment of lung cancer, which were far less successful in that they produced less
clear-cut evidence than their predecessors. In their paper, Helen Valier and Carsten
Timmermann look at both sets of trials, comparing the (often similar) problems the
MRC researchers encountered when organizing the different studies, and the various
ways in which they dealt with these. In contrast to the TB trials, lung cancer trials proved
34Marks, op. cit., note 33 above; Arthur A
Daemmrich, Pharmacopolitics: drug regulation in
the United States and Germany, Chapel Hill,
University of North Carolina Press, 2004.
35Daemmrich, op. cit., note 34 above, ch. 2;
Marks, op. cit., note 33 above, ch. 8.
36Lo ¨wy, op. cit., note 7 above; Peter Keating and
Alberto Cambrosio, ‘From screening to clinical
research: the cure of leukemia and the early
development of the cooperative oncology groups,
1955–1966’, Bull. Hist. Med., 2002, 76: 299–334.
See also Peter Keating and Alberto Cambrosio,
‘Cancer clinical trials: the emergence and
development of a new style of practice’, Bull. Hist.
Med., 2007, 81: 197–223, on p. 199.
37R F Bud, ‘Strategy in American cancer research
after World War Two: a case study’, Soc. Stud. Sci.,
1978, 8: 425–59; Ilana Lo ¨wy and Jean-Paul
Gaudillie `re, ‘Disciplining cancer: mice and the
practice of genetic purity’, in Jean-Paul Gaudillie `re
and Ilana Lo ¨wy (eds), The invisible industrialist:
manufactures and the production of scientific
knowledge, Basingstoke, Macmillan, 1998,
pp. 209–49.
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450a poor instrument of investigation, as the assessment of the effectiveness of combined
radiotherapy and surgery in relation to various radiotherapy regimes delivered inconclu-
sive results, which merely confirmed the status lung tumours acquired in the 1960s as
“untreatable” cancers because of the constant comparison made with the highly visible
and successful example of childhood leukaemia. The value of the MRC researchers’
attempts was therefore—Valier and Timmermann argue—less in the knowledge pro-
duced, than in their organizational significance. This distinction confirms Lo ¨wy’s obser-
vations on the palliative function of the trials, as well as her vision of a biomedical world
divided into two domains, the first a biological realm where research entities are easy to
control and manipulate, the second a clinical realm where cure is difficult to achieve and
research messy. Thus the post-war MRC trials participated in the transformation of
clinical research into a collective enterprise that relied on sophisticated forms of co-
ordination and division of labour, a development mirroring the hospital-based organiza-
tion of the NHS.
The “resistance” (a term invented by professional statisticians) of the French grands
cliniciens towards medical statistics is a common trope in the history of French medicine,
often linked to Claude Bernard’s famous plea against the use of percentage and compu-
tation in both experimental and clinical medicine.
38 Examining the clinical research pro-
gramme on leukaemia carried out under the leadership of Jean Bernard at the Saint-Louis
Hospital in Paris, Christelle Rigal’s paper shows us how in some circles of the medical
elite such disdain for numbers had by the 1960s become unacceptable. The internationa-
lization of leukaemia research was an important element in this transformation. Rigal’s
study reveals the “biomedical triangle” referred to earlier, describing as it does the devel-
opment of international studies launched by the American National Cancer Institute,
which tested molecules of American origin, but repeatedly mobilized a methodology
that was attributed to British inferential statistics. Local tinkering led to a combination
of RCTs and alternative designs that included historical controls, as well non-randomized
trials, a situation far from specific to France.
39 Specificity was not absent, however.
Unlike its American counterpart, French “clinical biomedicine” was not based on a
pharmaceutical culture of industrial standardization, but in a way similar to Britain, Rigal
argues, on an administrative culture of state planning.
What message can historians of twentieth-century medicine take from this selection of
articles? Our first conclusion is that it is worth embedding biomedicine within the
broader context of different post-war national health systems, and vice-versa, and look-
ing more precisely at the articulation as well as tensions between the three forms of
medicine, experimental, clinical, and social, which make up the western medical tradi-
tion. The second conclusion is that—contrary to what one might expect—in the era of
biomedicine, individual national patterns have had a relatively limited influence. The
moral and political economy of the post-war period stimulated the rapid internationaliza-
tion of biological research. This, in turn, resulted in similar challenges for different
38Jean-Paul Gaudillie `re, La me´decine et les
sciences, XIXe`–XXe` sie`cles, Paris, La De ´couverte,
2006, pp. 48–65, 89–92.
39Keating and Cambrosio, ‘From screening to
clinical research’, op. cit., note 36 above.
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451national scientific communities, if not similar practices, with the consequence that ana-
logous responses were worked out when “experimentalizing” clinical or public health
research. Our third and last conclusion is simply that recognizing this complex history
may be helpful in making the current wave of “biomedicalization” less radical and unex-
pected than social analysts are tempted to assume.
40
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